Back to News
Market Impact: 0.4
Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer
Source: Business Wire
Healthcare & BiotechRegulation & LegislationProduct Launches
Jemperli (dostarlimab-gxly) was approved in the U.S. as the first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer. The announcement reports no sales, financial guidance, or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.65
More News
- ’Panic’ selling hits Indonesian markets on MSCI expulsion threat
- Egyptian parliament delays vote on military support for Saudi Arabia
- We're buying more of a beaten-up stock before another overhang is lifted
- Capital One, General Motors are among the stocks reporting this week with momentum. Here are the others
- DeepSeek deep-sixed at all US federal civilian agencies
- Cboe’s Early Session for Single-Stock Options Makes Debut
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Sector Analysis, Improvements on Research Data, and Performance Enhancements
- Choosing an AI Copilot for Equity Research